This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CD123 x CD3
Description: XmAb14045 is an anti-CD123xCD3 bispecific antibody. Xencor's initial bispecific programs are tumor-targeted antibodies that contain both a tumor antigen binding domain (CD123, CD20, or CD38) and a cytotoxic T-cell binding domain (CD3). These bispecific antibodies activate T-cells for highly potent and targeted killing of malignant cells.
Xencor and Novartis
In June 2016, Xencor entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb14045 and XmAb13676.
Under the terms of the agreement, the parties will collaborate and share development costs for the worldwide development of XmAb14045 and XmAb13676, with Xencor maintaining U.S. commercialization rights and Novartis having commercialization rights in the rest of the world. Novartis will receive worldwide rights to Xencor's bispecific technology to develop and commercialize four additional targets selected by Novartis, one of which Xencor may elect to co-detail in the U.S. The bispecific collaboration will include molecular engineering by Xencor. Additionally, Novartis will receive a worldwide non-exclusive license to use Xencor's XmAb Fc technologies in up to ten molecules.
Xencor will receive a $150 million upfront payment and is eligible to receive clinical, regulatory...See full deal structure in Biomedtracker
Partners: Novartis AG
Additional information available to subscribers only: